Back to top
more

Evofem Biosciences (EVFM)

(Delayed Data from OTC)

$0.01 USD

0.01
667,905

0.00 (-3.00%)

Updated Aug 9, 2024 03:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Evofem Biosciences, Inc. [EVFM]

Reports for Purchase

Showing records 101 - 118 ( 118 total )

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

11/20/2018

Company Report

Pages: 8

Hug the Bear or Tackle the Bear

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

11/20/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

11/16/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

11/16/2018

Company Report

Pages: 7

Getting into Women''s Mindset When It Comes to Contraception

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

11/08/2018

Company Report

Pages: 6

3Q18 - AMPOWER Complete; Counting Down Until December

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

11/08/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

10/11/2018

Company Report

Pages: 7

There''s a Plan B, But Why Can''t There Be a Plan A?

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

10/11/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

10/01/2018

Company Report

Pages: 7

Join in Our Expert Call on the AMP-002 Confirmatory Phase 3 Trial

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

10/01/2018

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 111

08/29/2018

Company Report

Pages: 4

Rising Sexually-Transmitted Disease Rates Emphasize Novel Approach Need; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 112

08/06/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 113

08/06/2018

Company Report

Pages: 5

2Q 2018 Financial Results Reported; AMPOWER Study Ahead of Schedule; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 114

08/03/2018

Company Report

Pages: 6

2Q18 - Early Christmas Gift With Phase 3 AMP-002 Results in 4Q18

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 115

06/20/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 116

06/20/2018

Company Report

Pages: 24

Putting "I" Into Contraceptive Innovation; Initiating With Buy Rating

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 75.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 117

05/29/2018

Company Report

Pages: 4

1Q 2018 Results Reported; Financing Complete; PT Down on Share Increase; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Drugs

Record: 118

03/19/2018

Company Report

Pages: 25

Initiating at Buy and $15 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party
// eof